Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
Study identifier: NCT01477489
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Breast cancer with either
a) locoregional recurrence after previous mastectomy or,
b) inflammatory breast cancer status post mastectomy for which radiotherapy to the chest wall and regional nodes is planned as part of treatment.
Patients with Stage IV disease are eligible as long as they meet these criteria.
Type of study:
Phase I study
Veliparib twice daily and standard radiation treatment
New York City
Memorial Sloan Ketter Cancer Center
Contact: Dr. Beryl McCormick: 212-639-6756 firstname.lastname@example.org
Page updated 07/08/13
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.